Net Sales by Product

12 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

Net Sales by Product

Net sales by product:

The Company operates in a single industry engaging in the commercialization of pharmaceutical products for chronic conditions. Accordingly, the Company’s business is classified as a single reportable segment.

The following table presents net sales by product for each of the years ended December 31:

	Year ended December 31,
	2020			2019			2018
BELBUCA	$	136,128		$	97,538		$	45,988
% of net product sales	88.1		%	90.4		%	89.5		%
Symproic	14,709			8,061			$	—
% of net product sales	9.5		%	7.5		%	—		%
BUNAVAIL	3,737			2,289			5,422
% of net product sales	2.4		%	2.1		%	10.5		%
Net product sales	$	154,574		$	107,888		$	51,410

The Company discontinued marketing of BUNAVAIL in June 2020.